Physician profile
Tamara Brady
NPI 1427474949
$1,181.99
in general payments reported to CMS, 2019-2025
15 companies · $136 in 2025
The $136 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $75.57 · 2022: $171 · 2023: $700 · 2024: $99.47 · 2025: $136.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $495 · Travel and Lodging: $340 · Education: $100.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $495.17 |
| Travel and Lodging | $340.38 |
| Education | $100.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $456.38 | 2023 | Da Vinci Surgical System, Davinci Xi |
| Boston Scientific Corporation | $104.99 | 2022-2023 | Solyx Sis System |
| Abbvie INC. | $89.48 | 2022-2025 | |
| Janssen Biotech, INC. | $84.99 | 2023-2025 | Erleada |
| Telix Pharmaceuticals | $84.23 | 2023-2024 | Illuccix |
| Astellas Pharma US INC | $77.71 | 2021-2023 | Myrbetriq |
| Urogen Pharma, INC. | $72.21 | 2022 | |
| Progenics Pharmaceuticals, INC. | $55.78 | 2024-2025 | |
| Davol INC. | $29.83 | 2025 | Arista |
| Myriad Genetic Laboratories, INC. | $24.60 | 2023 | Prolaris |
| Koelis INC. | $24.19 | 2023 | |
| 180 Medical, INC. | $23.62 | 2022 | |
| Coloplast Corp | $20.21 | 2023 | Altis |
| Sumitomo Pharma America, INC. | $18.20 | 2024 | Gemtesa |
| Alnylam Pharmaceuticals INC. | $15.57 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tamara Brady listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.